Rasagiline: a guide to its use in Parkinson's disease.

Oral rasagiline (Azilect®) as monotherapy or as an adjunct to levodopa provides a useful option in the symptomatic treatment of adult patients with Parkinson's disease. In patients with early Parkinson's disease, monotherapy with rasagiline 1 mg/day improved symptoms of the disease relative to placebo. As adjunctive therapy to levodopa in patients with advanced Parkinson's disease, rasagiline 0.5 or 1 mg/day significantly reduces the total daily 'off' time. Rasagiline is generally well tolerated when administered as monotherapy or as adjunctive therapy.
AuthorsGillian M Keating, Katherine A Lyseng-Williamson, Sheridan M Hoy
JournalCNS drugs (CNS Drugs) Vol. 26 Issue 9 Pg. 781-5 (Sep 1 2012) ISSN: 1172-7047 [Print] New Zealand
PMID22834567 (Publication Type: Journal Article)
Chemical References
  • Antiparkinson Agents
  • Indans
  • Monoamine Oxidase Inhibitors
  • rasagiline
  • Levodopa
  • Dopamine
  • Administration, Oral
  • Antiparkinson Agents (administration & dosage, adverse effects, therapeutic use)
  • Dopamine (metabolism)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Humans
  • Indans (administration & dosage, adverse effects, therapeutic use)
  • Levodopa (administration & dosage, adverse effects, therapeutic use)
  • Monoamine Oxidase Inhibitors (administration & dosage, adverse effects, therapeutic use)
  • Parkinson Disease (drug therapy, enzymology)
  • Practice Guidelines as Topic
  • Randomized Controlled Trials as Topic
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password:
Type Validation Code Shown: